Trial · NCT03256253
Pregabalin as Treatment for Alcohol Use Disorder
NCT03256253, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2020-08-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pregabalin as Treatment for Alcohol Use Disorder. Trials, record NCT03256253. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03256253
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pregabalin as Treatment for Alcohol Use Disorder
- NCT number
- NCT03256253
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Alcohol Use Disorder
- Interventions
- Pregabalin
- First posted
- 2017-08-21
- Last updated
- 2020-08-31
- Results first posted
- 2020-08-13
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Dose of Pregabalin: | over the course of the 8 week trial or participants' length of participation | Defined as the highest amount of medication per day maintained for a 7 day period. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Maximum Dose of Pregabalin: | over the course of the 8 week trial or participants' length of participation | Data was available for 14 patients | milligrams | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Dose of Pregabalin: | Pregabalin | 571.4 | Standard Deviation 80.2 | milligrams |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pregabalin | 18 | |
| Overall Study | COMPLETED | Pregabalin | 6 | |
| Overall Study | NOT COMPLETED | Pregabalin | 12 |
Source ClinicalTrials.gov
Adverse events15
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | drowsiness | General disorders | Pregabalin | 4 | 15 | 4 |
| other | fogginess | General disorders | Pregabalin | 3 | 15 | 3 |
| other | dizziness | General disorders | Pregabalin | 3 | 15 | 3 |
| other | insomnia | General disorders | Pregabalin | 3 | 15 | 3 |
| other | back pain | Musculoskeletal and connective tissue disorders | Pregabalin | 2 | 15 | 2 |
| other | blurred vision | Eye disorders | Pregabalin | 2 | 15 | 2 |
| other | vivid dreams | General disorders | Pregabalin | 2 | 15 | 2 |
| other | dry mouth | General disorders | Pregabalin | 2 | 15 | 2 |
| other | fatigue | General disorders | Pregabalin | 2 | 15 | 2 |
| other | difficulty concentrating | General disorders | Pregabalin | 1 | 15 | 1 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pregabalin | 0 | 15 |
| Total, other adverse events | Pregabalin | 12 | 15 |
| Total, serious adverse events | Pregabalin | 0 | 15 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34092158 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03256253
GET https://conductscience.org/api/trials/v1/NCT03256253/registered